by Fred Dumais | Jan 29, 2024 | News Release
Record revenues of $54 million for fiscal 2023, up 94% over 2022 Revenues of $13.1 million for Q4-23, up 4% over Q4-22 Record annual adjusted gross profit of $16.9 million for 2023, compared to $9.4 million for 2022, up...
by Fred Dumais | Jan 22, 2024 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 22 janvier 2024 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui qu’elle divulguera ses résultats financiers et...
by Fred Dumais | Jan 22, 2024 | News Release
MONTREAL, QUEBEC , January 22, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended...
by Fred Dumais | Nov 20, 2023 | Communiqué de presse
Les initiatives de réduction des coûts et le réalignement organisationnel devraient générer des économies annuelles de plus de 2 millions $. MONTRÉAL (QUÉBEC), le 20 novembre 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société »...
by Fred Dumais | Nov 20, 2023 | News Release
Costs reduction initiatives and organizational realignment expected to generate annual savings exceeding $2 million. MONTREAL, QUEBEC, November 20, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical...
